Orion Corporation is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs). Committed to 'Building well-being,' Orion focuses on innovation and research to provide solutions for various therapeutic areas, including central nervous system disorders, oncology, and respiratory diseases. The company invests significantly in research and development to bring new treatments to patients worldwide.
Serves as the central hub for corporate management, global strategy, research and development (R&D) leadership, and administrative functions.
Modern R&D laboratories, advanced manufacturing units for certain products, and collaborative workspaces designed to foster innovation and efficiency. The campus is designed with sustainability considerations.
A science-driven and innovative environment emphasizing collaboration, continuous learning, high ethical standards, and employee well-being, aligning with its mission 'Building well-being'. Emphasis on expertise and patient-centricity.
The Espoo headquarters is pivotal for Orion's global operations, housing key decision-making processes, its primary research and development activities, and advanced manufacturing capabilities. It symbolizes the company's commitment to Finnish innovation.
Orion Corporation supports a wide range of functions globally, including research and development, manufacturing of APIs and finished dosage forms, extensive sales and marketing operations across Europe, and partnerships for distribution in North America, Asia-Pacific, and other regions. Its products are available in over 100 countries.
Orionintie 1A
Espoo
Uusimaa
Finland
Address: Orion Pharma (UK) Ltd, Suite 1, The Sefton Suite, Ground Floor, Rowlandson House, 289-293 Ballards Lane, London, N12 8NP, UK
To serve the UK healthcare market, ensuring availability and appropriate use of Orion's medicines, and engaging with local health authorities and stakeholders.
Address: Orion Pharma AB, Knistavägen 41-43, Box 520, SE-192 05 Sollentuna, Sweden
To cater to the Swedish pharmaceutical market, providing innovative medicines and support to patients and healthcare providers in Sweden.
Address: Orion Pharma GmbH, Notkestraße 9, 22607 Hamburg, Germany
To strengthen Orion's presence in the German market, providing therapies in key treatment areas and engaging with the German healthcare community.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Orion Corporation' leadership includes:
Orion Corporation has been backed by several prominent investors over the years, including:
In the past 12-18 months, Orion Corporation saw a key appointment to its Executive Management Board with Hao Wu joining as SVP, Global Operations, succeeding Juhani Kankaanpää who retired. Other changes to the board happened slightly earlier.
Discover the tools Orion Corporation uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Orion Corporation primarily uses the 'firstname.lastname@orion.fi' email format for its employees. This is a common format for Finnish and European companies.
firstname.lastname@orion.fi
Format
liisa.hurme@orion.fi
Example
90%
Success rate
Orion Corporation Stock Exchange Release • April 25, 2024
Orion Corporation published its interim report for the period January-March 2024, detailing financial performance and outlook. Net sales were EUR 300 million, and operating profit was EUR 62 million. The company reiterated its outlook for 2024....more
Orion Corporation Press Release • April 4, 2024
Orion announced that the US Food and Drug Administration (FDA) has agreed to the proposed regulatory path for Orion’s investigational new drug (IND), a new oral formulation of Nouryant® (opicapone), known as ODM-109. This formulation aims to assist Parkinson's patients who have difficulties swallowing....more
Orion Corporation Press Release • March 13, 2024
Orion Corporation and Newel Health announced a strategic collaboration to develop digital therapy solutions for patients with Parkinson's disease. The partnership aims to combine Orion's pharmaceutical expertise with Newel Health's digital health technology....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Orion Corporation, are just a search away.